Mr. Jim Durward reports

NDATALYZE CORP. ("NDAT" OR THE "CORPORATION") (CSE:NDAT) (OTCQB:NDATF) ANNOUNCES POSITIVE CLINICAL STUDY RESULTS, AND MINDBALANCED UPDATE

Ndatalyze Corp. has provided the following updates.

Positive clinical study results

The attached table predicts depression probabilities using two different approaches:

1. The original YMI expert-guided approach where the predictive scoring is guided by psychoanalytical experts in advance of the application of machine learning;
2. The supervised approach where no expert guidance is provided in advance of machine learning application.

The attached table shows that the machine learning results support the YMI expert-guided results and that the YMI approach outperforms the machine learning approach. Both approaches used the same ground truth targets (that is, depression diagnoses by only psychiatrists and psychologists while excluding primary physician diagnoses). These excellent results support two product paths, both of which require only occasional machine learning calibration, thereby reducing complexity and cost:

• Advanced digital therapeutics -- an on-line platform for correlation of various data types used to design highly personalized on- and off-label treatment protocols for multiple mental conditions and non-drug treatment modalities such as transcranial magnetic stimulation and trigeminal nerve stimulation, and seasonal affective disorder light therapies. DTx product manufacturers are being contacted.
• As an adjunctive mental health assessment tool for use by primary care physicians and family doctors who are often a patient's first contact with the mental health system and who are seeking advanced technologies to help significantly reduce depression mis/overdiagnoses that are believed to be a root cause of inappropriate prescribing and poor treatment outcomes. The company believes that preferred point of entry is through electronic medical records, and the corporation is taking steps in this regard. The product, YMI, is on-line now and available for integration.

James Durward, president, commented: "From the beginning, our goal was to combine the power of a purpose-built database with machine learning to go beyond the limitations of human assessments, and I believe we have accomplished this goal. We are also now in the position to correlate known outcomes from a variety of treatment modalities to predict higher-precision treatment protocols before treatment. We believe this to be the future of precision mental health assessment and treatment."

Mindbalanced: Regarding the acquisition agreement dated April 15, 2024, the acquisition was completed in anticipation of Mindbalanced enrolling multiple TMS clinics, thereby providing a channel for YMI's correlation to TMS treatment protocols and entry into the U.S. market. Since the acquisition closed, Mindbalanced clinic enrolment has not met expectations, and the corporation is currently negotiating the reversal of the transaction in a manner that reduces the current issued and outstanding common shares to the level immediately preceding the acquisition. It is anticipated there will be no material cost for doing so.

We seek Safe Harbor.